Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Article
  • Cited by 5

  • Get access
    Add to cart £25.00
    Check if you have access via personal or institutional login
    Log in Register

The value of serum N-terminal pro-brain natriuretic peptide levels in the differential diagnosis and follow-up of congestive cardiac failure and respiratory distress due to pulmonary aetiologies in infants and children

  • Melike Sezgin Evim (a1), Birsen Ucar (a1), Zübeyir Kilic (a1) and Omer Colak (a1)

Abstract

Objective

We aimed to determine whether N-terminal pro-brain natriuretic peptide can differentiate between cardiac and pulmonary aetiologies of dyspnoea, if N-terminal pro-brain natriuretic peptide can be used for evaluating the effect of treatment in cardiac failure, and for predicting severe pulmonary diseases that are complicated by cardiac failure.

Methods

In all, 76 children with dyspnoea were enrolled; 41 of them suffered cardiac failure – 25 caused by cardiac disease, 16 caused by pulmonary disease – and 35 had dyspnoea due to pulmonary disease. The control group consisted of 32 children. We calculated Ross scores, analysed N-terminal pro-brain natriuretic peptide levels, and evaluated left ventricular systolic functions by echocardiography.

Results

N-terminal pro-brain natriuretic peptide levels were significantly higher in children with cardiac failure than in those with pulmonary disease and in controls (medians 7321, 241, 87.71 picograms per millilitre, respectively), were higher in children with cardiac failure due to pulmonary disease than in those with only pulmonary disease (medians 2728, 241 picograms per millilitre, respectively), and were higher in children who died from cardiac failure than in survivors (p < 0.05). After treatment of cardiac failure, N-terminal pro-brain natriuretic peptide levels decreased significantly (p < 0.001). The cut-off level of N-terminal pro-brain natriuretic peptide for differentiating cardiacfailure from pulmonary disease was 726.8 picograms per millilitre, sensitivity 100%, specificity 94.3%.

Conclusions

N-terminal pro-brain natriuretic peptide levels can differentiate dyspnoea due to cardiac failure from pulmonary diseases. It can also be used to monitor the effects of treatment of cardiac failure and to estimate the prognosis, as well as to predict pulmonary diseases that are complicated with cardiac failure.

Copyright

COPYRIGHT: © Cambridge University Press 2010

Corresponding author

Correspondence to: Dr M. S. Evim, Faculty of Medicine, Department of Pediatric Cardiology, Eskisehir Osmangazi University, 26480, Eskisehir, Turkey. Tel: +90 222 2392979/2758; Fax: +90 222 2393772; E-mail: melikevim@yahoo.com

References

Hide All
1. Francis, GS, Gassler, JP, Sonnenblick, EH. Heart Failure. In Fuster C, Alexander RW, O’Rourke RA (eds). The Heart, 10th edn. International Edition, McGraw-Hill, New York, 2001; 653–685.
2. Jefferies, JL, Chang, AC. The neurohormonal axis and biochemical markers of heart failure. Cardiol Young 2005; 15: 333–344.
3. Valderheyden, M, Bartunek, J, Goethals, M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6: 261–268.
4. Hall, C. Essential biochemistry and physiology of (NT-pro) brain natriuretic peptide. Eur J Heart Fail 2004; 6: 257–260.
5. Weber, M, Hamm, C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843–849.
6. Ambrose, TM. A review of the clinical utility of NT-proBNP in the diagnosis, prognosis and therapy monitoring of patients with congestive heart failure. J Clin Ligand Assay 2003; 25: 160–166.
7. Cowie, MR, Struthers, AD, Wood, DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–1353.
8. Mir, TS, Marohn, S, Laer, S, Eiselt, M, Grollmus, O, Weil, J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and children with congestive heart failure. Pediatrics 2002; 110: 76–81.
9. Mueller, T, Gegenhuber, A, Poelz, W, Haltmayer, M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005; 91: 606–612.
10. Murray, H, Cload, B, Collier, CP, Sivilotti, ML. Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea. CJEM 2006; 8: 251–258.
11. Moe, GM. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006; 21: 208–214.
12. Koulouri, S, Acherman, RJ, Wong, PC, Chan, LS, Lewis, AB. Utilty of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric with respiratory distress. Pediatr Cardiol 2004; 25: 341–346.
13. Cohen, S, Springer, C, Avital, A. Amino-terminal pro-brain natriuretic peptide: Heart or lung disease in pediatric respiratory distress? Pediatrics 2005; 115: 1347–1350.
14. Dreyer, WJ, Fisher, DJ. Clinical Recognition and management of chronic congestive heart failure. In Garson A, Bricker JT, Fisher DJ and Neish SR (eds). The science and practice of pediatric cardiology, 2nd edn. Williams and Wilkins, Baltimore, 1998; 1582–1587.
15. James, N, Smith, M. Treatment of heart failure in children. Current Paediatrics 2005; 15: 539–548.
16. Koch, A, Singer, H. Normal values of B type natriuretic peptide in infants, children and adolescents. Heart 2003; 89: 875–878.
17. Mir, TS, Flato, M, Falkenberg, J, et al. Plasma consentrations of N-terminal brain natriuretic peptide in healthy children, adolescents and young adults: effect of age and gender. Pediatr Cardiol 2006; 27: 73–77.
18. Cowley, CG, Bradley, JD, Shaddy, RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004; 25: 336–340.
19. Koch, A, Zink, S, Singer, H. B-type natriuretic peptide in paediatric patents with congenital heart disease. Eur Heart J 2006; 27: 861–866.
20. Shann, F, MacGregor, D, Richens, J, Coakley, J. Cardiac failure in children with pneumonia in Papua New Guinea. Pediatr İnfect Dis J 1998; 17: 1141–1443.
21. İlten, F, Şenocak, F, Zorlu, P, Teziç, T. Cardiovascular changes in children with pneumonia. Turk J Pediatr 2003; 45: 306–310.
22. Wang, YL, Liu, W, Jiang, P. Myokardial protective effect of puerarin injection in children with severe pneumonia. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25: 502–504.
23. Ross, RD, Bollinger, RO, Pinsky, WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13: 72–75.
24. Laer, S, Mir, TS, Behn, F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 916–922.
25. An, JD, Zhang, YP, Zhou, JH. Levels of serum brain natriuretic peptide in children with congestive heart failure or with severe pneumonia. Zhongguo Dang Dai Er Ke Za Zhi 2006; 8: 201–204.
26. Meliones, JN, Cheifetz, IM. Pulmonary physiology and heart-lung interactions. In Garson A, Bricker JT, Fisher DJ and Neish SR (eds). The Science and Practice of Pediatric Cardiology, 2nd edn. Williams and Wilkins, Baltimore, 1998; 279–312.
27. Seedat, MA, Feldman, C, Skoularigis, J, Prommnitz, DA, Smith, C, Zwi, S. A study of acute community-acquired pneumonia, including details of cardiac changes. Q J Med 1993; 86: 669–675.
28. Bayes-Genis, A, Santalo-Bel, M, Zapico-Muniz, E, et al. N-terminal probrain natriuretic peptide in the emergency diagnosis and in-hospital monitoring of patients with dysnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6: 301–308.
29. Bettencourt, P. NT pro-BNP and BNP: biomakers for heart failure management. Eur J Heart Fail 2004; 6: 359–363.
30. Suda, K, Matsumura, M, Matsumoto, M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45: 249–254.
31. Maeda, K, Tsutamoto, T, Wada, A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587–1593.
32. Pfister, R, Scholz, M, Wielckens, K, Erdmann, E, Schneider, CA. Use of NT pro-BNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6: 289–293.
33. Seino, Y, Ogawa, A, Yamashita, T, et al. Application of NT pro-BNP and BNP measurements in cardiac care: a more discerning marker of the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6: 295–300.
34. Wu, YR, Chen, SB, Huang, MR, Zhang, YQ, Sun, K, Chen, S. Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects. Zhonghua Er Ke Za Zhi 2005; 43: 161–164.
35. Maisel, A. B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. J Card Fail 2001; 7: 183–193.
36. Mir, TS, Falkenberg, J, Friedrich, B, et al. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young 2005; 15: 396–401.

Keywords

  • Cited by 5

  • Get access
    Add to cart £25.00
    Check if you have access via personal or institutional login
    Log in Register

The value of serum N-terminal pro-brain natriuretic peptide levels in the differential diagnosis and follow-up of congestive cardiac failure and respiratory distress due to pulmonary aetiologies in infants and children

  • Melike Sezgin Evim (a1), Birsen Ucar (a1), Zübeyir Kilic (a1) and Omer Colak (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed